+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Monoclonal Antibodies for Plaque Psoriasis Market - Global Forecast 2026-2032- Product Image
Monoclonal Antibodies for Plaque Psoriasis Market - Global Forecast 2026-2032- Product Image
Sale

Monoclonal Antibodies for Plaque Psoriasis Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6147894
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Monoclonal Antibodies for Plaque Psoriasis Market is projected to reach USD 16.02 Billion in 2026. It is expected to continue growing at a CAGR of 11.99%, reaching USD 31.50 Billion by 2032.

Plaque Psoriasis Antibody Therapy: Executive Overview

Monoclonal antibodies have reshaped plaque psoriasis care by selectively targeting inflammatory pathways associated with disease activity. Their clinical value is assessed through improvements in skin clearance, durability of response, safety, dosing convenience, comorbidity considerations, and suitability for different patient profiles. Treatment decisions increasingly combine disease severity, prior therapy, patient preferences, access conditions, and long-term disease management goals.

How Precision Immunology Is Changing Plaque Psoriasis Care

The therapeutic landscape has shifted from broad immune suppression toward pathway-specific biologic treatment. Interleukin-directed approaches have expanded options for patients who require systemic therapy, while clinical practice has placed greater emphasis on rapid response, sustained control, treatment persistence, and quality-of-life outcomes. Care is also becoming more individualized as clinicians weigh psoriatic arthritis risk, cardiometabolic comorbidities, infection history, reproductive considerations, and previous treatment exposure.

Artificial Intelligence and the Next Layer of Treatment Personalization

Artificial intelligence can support plaque psoriasis management by improving lesion assessment, standardizing severity scoring, identifying patterns in treatment response, and helping clinicians interpret longitudinal patient data. Its practical value depends on representative image datasets, transparent validation, privacy safeguards, and integration into clinical workflows. AI should complement-not replace-clinical judgment, particularly when diagnosis is uncertain, comorbidities are complex, or treatment risks require individualized evaluation.

Regional Differences in Access, Practice, and Evidence Use

North America generally combines advanced specialist infrastructure with strong use of biologic therapies, although payer authorization and treatment sequencing can influence access. Europe emphasizes guideline-based care, health-technology assessment, biosimilar adoption, and national reimbursement frameworks. Asia-Pacific shows substantial variation between highly developed specialist systems and settings where diagnosis, monitoring, and affordability remain barriers. Latin America faces uneven reimbursement, specialist availability, and distribution. The Middle East is characterized by concentrated specialist capacity alongside differing public and private access pathways, while Africa continues to contend with limited dermatology coverage, diagnostic gaps, and constrained availability of advanced therapies. Across all regions, local guidelines, procurement systems, pharmacovigilance, and patient support affect real-world use.

Group-Level Signals Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets reflect wide differences in healthcare financing, specialist density, regulatory maturity, and biologic availability, making localized access strategies important. BRICS countries combine large and diverse patient populations with distinct reimbursement systems, domestic manufacturing capabilities, and uneven specialist access. The European Union is shaped by shared regulatory principles but heterogeneous national reimbursement and health-technology assessment decisions. G7 countries generally have mature dermatology services and established biologic pathways, while still managing affordability, authorization criteria, and treatment persistence. GCC systems often have comparatively well-resourced tertiary care in major centers but varied national coverage and geographic access. NATO members span highly diverse health systems, so alliance membership does not imply uniform treatment access or clinical practice.

Country-Level Priorities for Plaque Psoriasis Treatment

Australia and Canada must balance geographically dispersed populations with specialist access and public or private reimbursement requirements. Brazil and Mexico face regional disparities in dermatology capacity, coverage, and continuity of care. China and India combine expanding specialist services with major differences between urban and rural access, affordability, and diagnostic consistency. Japan and South Korea have sophisticated clinical infrastructure, with local regulatory, prescribing, and reimbursement considerations shaping uptake. France, Germany, Italy, Spain, and the United Kingdom operate within mature European care systems but differ in assessment procedures, prescribing pathways, and regional implementation. Russia’s access environment is influenced by healthcare financing, supply continuity, and specialist distribution. In the United States, insurance design, prior authorization, specialty pharmacy processes, and patient affordability remain central practical considerations.

Actions for Leaders: Improve Outcomes Through Access, Evidence, and Execution

Industry leaders should align clinical development and service design with outcomes that matter to patients and clinicians, including durable skin clearance, functional improvement, treatment persistence, and quality of life. They should strengthen comparative and real-world evidence, segment support around patient and provider needs, and prepare reimbursement dossiers that address clinical value as well as budget impact without relying on unsupported claims. Operational priorities include resilient supply planning, transparent safety communication, responsible patient education, and partnerships that improve diagnosis and specialist referral. Digital and AI tools should be introduced with clinical validation, governance, cybersecurity, and clear accountability.

Methodology for a Decision-Useful Executive Summary

This summary uses a structured synthesis of the supplied market scope-monoclonal antibodies for plaque psoriasis-combined with established clinical, regulatory, healthcare-access, and treatment-delivery considerations. Insights are organized across therapeutic change, artificial intelligence, regions, country groups, and specified countries. Claims are framed at a qualitative level and avoid market estimates, market shares, forecasts, company-specific comparisons, and unsupported numerical assertions. Interpretation should be updated against current treatment guidelines, regulatory decisions, reimbursement policies, peer-reviewed evidence, and local epidemiological data before strategic or clinical use.

Conclusion: Build Patient-Centered, Evidence-Led Biologic Care

Monoclonal antibodies remain central to the evolution of systemic plaque psoriasis treatment because they enable targeted intervention and support durable disease control for appropriate patients. Their broader impact will depend not only on therapeutic performance, but also on affordability, equitable diagnosis, specialist capacity, monitoring, patient preferences, and responsible use of data and AI. Leaders who connect robust evidence with practical access and locally appropriate delivery will be best positioned to improve outcomes across diverse healthcare systems.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Monoclonal Antibodies for Plaque Psoriasis Market, by Drug Class
7.1. Introduction
7.2. Il-17 Inhibitors
7.2.1. Brodalumab
7.2.2. Ixekizumab
7.2.3. Secukinumab
7.3. Il-23 Inhibitors
7.3.1. Guselkumab
7.3.2. Risankizumab
7.3.3. Tildrakizumab
7.4. Tnf Alpha Inhibitors
7.4.1. Adalimumab
7.4.2. Certolizumab
7.4.3. Etanercept
7.4.4. Golimumab
7.4.5. Infliximab
8. Monoclonal Antibodies for Plaque Psoriasis Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Subcutaneous
9. Monoclonal Antibodies for Plaque Psoriasis Market, by Disease Severity
9.1. Introduction
9.2. Moderate
9.3. Severe
10. Monoclonal Antibodies for Plaque Psoriasis Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Dermatology Clinics
10.4. Hospitals
11. Monoclonal Antibodies for Plaque Psoriasis Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.5. Specialty Pharmacies
12. Monoclonal Antibodies for Plaque Psoriasis Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Monoclonal Antibodies for Plaque Psoriasis Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Monoclonal Antibodies for Plaque Psoriasis Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Bausch Health Companies Inc.
16.3. Eli Lilly and Company
16.4. Johnson & Johnson
16.5. Novartis AG
16.6. Sun Pharmaceutical Industries Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Monoclonal Antibodies for Plaque Psoriasis Market, Years Considered for the Study
FIGURE 2. Global Monoclonal Antibodies for Plaque Psoriasis Market, Research Design
FIGURE 3. Global Monoclonal Antibodies for Plaque Psoriasis Market, Research Framework
FIGURE 4. Global Monoclonal Antibodies for Plaque Psoriasis Market, Data Triangulation
FIGURE 5. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2025 vs 2032 (%)
FIGURE 11. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Monoclonal Antibodies for Plaque Psoriasis Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Monoclonal Antibodies for Plaque Psoriasis Market Segmentation & Coverage
TABLE 2. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 3. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Il-17 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Il-17 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Il-17 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Brodalumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Brodalumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Brodalumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Ixekizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Ixekizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Ixekizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Secukinumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Secukinumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Secukinumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Il-23 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Il-23 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Il-23 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Guselkumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Guselkumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Guselkumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Risankizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Risankizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Risankizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Tildrakizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Tildrakizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Tildrakizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Tnf Alpha Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Tnf Alpha Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Tnf Alpha Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Adalimumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Adalimumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Adalimumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Certolizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Certolizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Certolizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Etanercept Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Etanercept Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Etanercept Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Golimumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Golimumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Golimumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Infliximab Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Infliximab Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Infliximab Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 47. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 54. Global Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Dermatology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Dermatology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Dermatology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 71. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Specialty Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Specialty Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Specialty Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 95. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 96. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 97. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 98. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 99. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 100. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. North America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 104. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 105. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 106. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 107. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 108. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 109. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Latin America Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 113. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 114. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 115. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 116. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 117. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 118. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Europe Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 122. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 123. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 124. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 125. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 127. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. Middle East Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 131. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 132. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 133. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 134. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 136. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Africa Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 141. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 142. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 143. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 144. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 145. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 146. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. ASEAN Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 150. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 151. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 152. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 153. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 154. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 155. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. GCC Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 159. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 160. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 161. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 162. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 163. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 164. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. European Union Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 168. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 169. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 170. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 171. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 172. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 173. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. BRICS Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 176. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 177. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 178. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 179. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 180. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 181. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 182. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. G7 Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 186. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 187. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 188. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 189. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 190. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 191. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. NATO Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. Global Monoclonal Antibodies for Plaque Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 194. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 195. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 196. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 197. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 198. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 199. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 200. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 201. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. United States Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 204. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 205. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 206. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 207. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 208. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 210. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Canada Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 213. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 214. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 215. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 216. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 217. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 218. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 219. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Mexico Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 222. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 223. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 224. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 225. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 226. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 228. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Brazil Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 231. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 232. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 233. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 234. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 235. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 236. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 237. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. United Kingdom Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 240. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 241. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 242. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 243. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 244. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 245. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 246. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. Germany Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. France Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 249. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 250. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 251. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 252. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 253. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 254. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 255. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. France Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 257. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 258. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 259. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 260. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 261. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 262. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 263. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 264. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. Russia Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 267. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 268. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 269. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 270. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 271. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 273. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. Italy Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 275. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 276. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 277. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 278. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 279. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 280. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 281. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 282. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Spain Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. China Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 285. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 286. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 287. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 288. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 289. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 290. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 291. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. China Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 293. India Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 294. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 295. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-17 Inhibitors, 2017-2032 (USD Million)
TABLE 296. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by Il-23 Inhibitors, 2017-2032 (USD Million)
TABLE 297. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by Tnf Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 298. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 299. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 300. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. India Monoclonal Antibodies for Plaque Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. Japan Monoclonal Antibodies for Plaque Psoriasis Market Size, 2017-203

Companies Mentioned

  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Novartis AG
  • Sun Pharmaceutical Industries Limited

Related Topics

Related Reports

Psoriasis Biosimilars Market Report 2026 - Product Image

Psoriasis Biosimilars Market Report 2026

  • Report
  • 250 Pages
  • Global
From
TNF Inhibitors for the Treatment of Plaque Psoriasis Market - Global Forecast 2026-2032 - Product Image

TNF Inhibitors for the Treatment of Plaque Psoriasis Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Global Psoriasis Treatment Market Outlook, 2031 - Product Image

Global Psoriasis Treatment Market Outlook, 2031

  • Report
  • 209 Pages
  • Global
From
Chronic Plaque Psoriasis Market Report 2026 - Product Image

Chronic Plaque Psoriasis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.